References
1)
Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of
coronavirus disease (COVID-19) outbreak. J Autoimmun 2020;109:102433,2.
2)Zhang P, Zhu L, Cai J, Lei F, Qin JJ, Xie J,et al. Association of
inpatient use of angiotensin converting enzyme inhibitors and
angiotensin II receptor blockers with mortality among patients with
hypertension hospitalized with COVID-19. Circ Res 2020.
3) Sommerstein R, Kochen MM, Messerli FH, Gra¨ni C. Coronavirus disease
2019 (COVID-19): do angiotensin-converting enzyme inhibitors/angiotensin
receptor blockers have a biphasic effect. J Am Heart Assoc
2020;9:e016509.
4)Reynolds HR, Adhikari S, Pulgarin C, et al.
Renin–angiotensin–aldosterone system inhibitors and risk of Covid-19.
N Engl J Med. DOI: 10.1056/NEJMoa2008975.
5) Morrow DA, Velazquez EJ, DeVore AD, Desai AS, Duffy CI, Ambrosy AP,
Gurmu Y, McCague K, Rocha R, Braunwald E. Clinical outcomes in patients
with acute decompensated heart failure randomly assigned to
sacubitril/valsartan or enalapril in the PIONEER-HF Trial. Circulation
2019;139: 2285–2288.
6) Shi S, Qin M, Shen B, Cai Y, Liu T, Yang F, Gong W, Liu X, Liang J,
Zhao Q, Huang H, Yang B, Huang C. Association of cardiac injury with
mortality in hospital patients with COVID-19 in Wuhan, China. JAMA
Cardiol 2020;doi:10.1001/jamacardio. 2020.0950.
7) Gao L, Jiang D, Wen XS, Cheng XC, Sun M, He B, You LN, Lei P, Tan XW,
Qin S, Cai GQ, Zhang DY. Prognostic value of NT-proBNP in patients with
severe COVID-19. Respir Res 2020; 21:83..
8) Li N, Zhang Y, Fan S, Xing J, Liu H BNP and NT-pro BNP levels in
patients with sepsis Front Biosci (Landmark Ed). 2013;18:1237-43.
9) Jensen J, Ma LP, Fu ML, Svaninger D, Lundberg PA, Hammarsten O.
Inflammation increases NT-proBNP and NT-pro BNP/BNP ratio Clin Res
Cardiol. 2010;99(7):445-52. doi: 10.1007/s00392-010-0140-z. Epub 2010
Mar 13.
10) Singh JSS, Burrell LM, Cherif M, Squire IB, Clark AL, Lang CC.
Sacubitril/valsartan:beyond natriuretic peptide Heart.
2017;103(20):1569-1577.
11) L. Mezzasoma, C. Antognelli,and V. Talesa Novel Role for Brain
Natriuretic Peptide: Inhibition of IL-1𝛽 Secretion via Downregulation of
NF-kB/Erk 1/2 and NALP3/ASC/Caspase-1 Activation in Human THP-1 Monocyte
Mediators of Inflammation. 2017.